<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010581</url>
  </required_header>
  <id_info>
    <org_study_id>SC12267-5-2009</org_study_id>
    <nct_id>NCT01010581</nct_id>
  </id_info>
  <brief_title>SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>COMPONENT</acronym>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>4SC AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>4SC AG</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the efficacy, safety and pharmacokinetics of SC12267&#xD;
      (4SC-101, 35 mg) in combination with methotrexate in comparison to methotrexate alone in the&#xD;
      treatment of patients suffering from Rheumatoid Arthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of SC12267 (4SC-101) in combination with methotrexate in patients with RA</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety of the combination of SC12267 (4SC-101) and methotrexate in patients with RA</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the plasma concentration (trough value) of SC12267 (4SC-101) after once daily application in combination with methotrexate after once weekly administration.</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SC12267 (4SC-101) + Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Methotrexate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC12267 (4SC-101)</intervention_name>
    <description>oral administration</description>
    <arm_group_label>SC12267 (4SC-101) + Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Placebo + Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Placebo + Methotrexate</arm_group_label>
    <arm_group_label>SC12267 (4SC-101) + Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Placebo + Methotrexate</arm_group_label>
    <arm_group_label>SC12267 (4SC-101) + Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Patients with active RA of functional classes I, II or III according to the criteria&#xD;
             of American Rheumatism Association for RA&#xD;
&#xD;
          -  DAS28(ESR) ≥ 4.5 (DAS28 formula with 4 variables using ESR)&#xD;
&#xD;
          -  Patients who have received weekly doses of MTX (10-25 mg/week) for a minimum of 3&#xD;
             months prior to Day 1 dosing, and who have received a stable MTX dose of 10-25 mg/week&#xD;
             without any change in route or change in folic acid supplementation for at least 6&#xD;
             weeks prior to Day 1 dosing&#xD;
&#xD;
          -  Patients may receive up to 10 mg/day of oral prednisolone or steroid equivalent. Dose&#xD;
             must have been stable for at least 30 days and must not be changed during the washout,&#xD;
             screening and treatment periods, unless dictated by tolerability requirements&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Patients with RA of functional classes IV according to the criteria of American&#xD;
             Rheumatism Association for RA&#xD;
&#xD;
          -  Patients who have received any of the following treatments must abide by the indicated&#xD;
             washout period:&#xD;
&#xD;
               1. Leflunomide requires a 6 month washout period prior to Day 1 dosing&#xD;
&#xD;
               2. Oral or injectable gold, azathioprine, penicillamine, anakinra require a 30 day&#xD;
                  washout period prior to Day 1 dosing&#xD;
&#xD;
               3. Cyclosporine, abatacept, etanercept, adalimumab, infliximab, and rituximab&#xD;
                  require a 60 day washout period prior to Day 1 dosing&#xD;
&#xD;
               4. Cyclophosphamide requires a 180 day washout period prior to Day 1 dosing&#xD;
&#xD;
               5. Parenteral or intra-articular corticosteroids require a 30 day washout period&#xD;
                  prior to Day 1 dosing&#xD;
&#xD;
          -  Receipt of the following drugs within 4 weeks prior to dosing:&#xD;
&#xD;
               1. Sulfasalazine&#xD;
&#xD;
               2. Hydroxychloroquine&#xD;
&#xD;
               3. Use of corticosteroids &gt; 10 mg/day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanisław Sierakowski, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centrum Miriada, Prywatny Gabinet Specjalistyczny, Bialystok, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MHAT &quot;Kaspela&quot; Department of Rheumatology</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consulting Centre &quot;Sv. Anna&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Multiprofile Transport Hospital &quot;Tsar Boris III&quot; Internal Clinic</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sveti Ivan Rilski&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Outpatient Clinic</name>
      <address>
        <city>Hlučín</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Center Mediscan</name>
      <address>
        <city>Praha 11</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Miriada, Prywatny Gabinet Specjalistyczny</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowieckie Centrum Badań Klinicznych s.c.</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Śląskie Centrum Osteoporozy</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Ośrodek ALL-MED</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Reumed</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr Hab. n. m. Leszek Szczepański</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poznański Ośrodek Medyczny NOVAMED</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Reumatologiczny</name>
      <address>
        <city>Sopot</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ &quot;Nasz Lekarz&quot;</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Leczenia Chorób Cywilizacyjnych Sp. z o. o. S. K. A.</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Osteomed NZOZ Lecznica Specjalistów</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Materia Medica</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Hospital Sf. Maria</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Hospital &quot;Prof. Dr. Gerota&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Duomedical</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ianuli Med Consult</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Hospital Cluj - Rheumatology clinic</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical County Hospital of Targoviste</name>
      <address>
        <city>Targoviste, Dambovita</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Prof. Dr. Mioara Banciu</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2009</study_first_posted>
  <last_update_submitted>February 29, 2012</last_update_submitted>
  <last_update_submitted_qc>February 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2012</last_update_posted>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>SC12267</keyword>
  <keyword>4SC-101</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

